Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (pf 0495061), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Trial Profile

Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (pf 0495061), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bococizumab (Primary)
  • Indications Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRE-2
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 May 2018 Results (n=9738) assessing residual inflammatory risk among 9,738 patients participating in the studies of PCSK9 Inhibition and the Reduction of Vascular Events (SPIRE)-1 and -2, were published in the Circulation.
    • 18 May 2017 This trial has been completed in Sweden (end date: 3 Apr 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top